DE69838338D1 - Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen - Google Patents

Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen

Info

Publication number
DE69838338D1
DE69838338D1 DE69838338T DE69838338T DE69838338D1 DE 69838338 D1 DE69838338 D1 DE 69838338D1 DE 69838338 T DE69838338 T DE 69838338T DE 69838338 T DE69838338 T DE 69838338T DE 69838338 D1 DE69838338 D1 DE 69838338D1
Authority
DE
Germany
Prior art keywords
antimykotica
mushroom
induced tissue
skin injection
tissue skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838338T
Other languages
English (en)
Other versions
DE69838338T2 (de
Inventor
Jens Ponikau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Jens Ponikau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jens Ponikau filed Critical Jens Ponikau
Publication of DE69838338D1 publication Critical patent/DE69838338D1/de
Application granted granted Critical
Publication of DE69838338T2 publication Critical patent/DE69838338T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
DE69838338T 1997-10-22 1998-10-22 Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen Expired - Lifetime DE69838338T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6270997P 1997-10-22 1997-10-22
US62709P 1997-10-22
US6341497P 1997-10-28 1997-10-28
US6341897P 1997-10-28 1997-10-28
US63414P 1997-10-28
US63418P 1997-10-28
US8327298P 1998-04-28 1998-04-28
US83272P 1998-04-28
US8639798P 1998-05-22 1998-05-22
US86397P 1998-05-22
PCT/US1998/022403 WO1999020261A2 (en) 1997-10-22 1998-10-22 Use of antigunal agents for the topial treatment of fungus-induced mucositis

Publications (2)

Publication Number Publication Date
DE69838338D1 true DE69838338D1 (de) 2007-10-11
DE69838338T2 DE69838338T2 (de) 2008-05-21

Family

ID=27535591

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838338T Expired - Lifetime DE69838338T2 (de) 1997-10-22 1998-10-22 Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen

Country Status (28)

Country Link
US (9) US20010006944A1 (de)
EP (2) EP1857113A3 (de)
JP (3) JP2001520188A (de)
KR (4) KR100883149B1 (de)
CN (1) CN1143679C (de)
AP (1) AP2000001805A0 (de)
AT (1) ATE371457T1 (de)
AU (1) AU1195999A (de)
BG (1) BG104371A (de)
BR (1) BR9814615A (de)
CA (1) CA2308201C (de)
DE (1) DE69838338T2 (de)
DK (1) DK1024814T3 (de)
EA (1) EA200000439A1 (de)
EE (1) EE200000253A (de)
ES (1) ES2292210T3 (de)
HK (1) HK1029935A1 (de)
HU (1) HUP0004170A3 (de)
ID (1) ID26104A (de)
IL (2) IL135774A0 (de)
IS (1) IS5463A (de)
NO (1) NO325714B1 (de)
OA (1) OA11351A (de)
PL (1) PL340606A1 (de)
PT (1) PT1024814E (de)
SK (1) SK5732000A3 (de)
TR (1) TR200001117T2 (de)
WO (1) WO1999020261A2 (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
PL340606A1 (en) * 1997-10-22 2001-02-12 Jens Ponikau Methods of and materials for treating and preventing mucositis
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
AU5975700A (en) * 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
SE521431C2 (sv) * 1999-12-02 2003-11-04 Sca Hygiene Prod Ab Användning av en pH-buffrande substans för att förhindra hudinfektioner orsakade av Candida Albicans
US6930125B2 (en) * 2000-01-14 2005-08-16 John F. Hunt Airway alkalinization as a therapy for airway diseases
WO2001060395A2 (en) * 2000-02-18 2001-08-23 Eli Lilly And Company Methods of treatment for non-invasive fungus-induced mucositis with cyclohexapeptide antifungal agents
US7048953B2 (en) * 2000-04-03 2006-05-23 Inhalation, Inc. Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US7150888B1 (en) 2000-04-03 2006-12-19 Inhalation, Inc. Methods and apparatus to prevent colds, influenzaes, tuberculosis and opportunistic infections of the human respiratory system
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6767537B2 (en) 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
AU8298801A (en) * 2000-07-26 2002-02-05 John K Vyden Methods for treating atopic disorders
WO2002022118A1 (de) * 2000-09-14 2002-03-21 Waldemar Gottardi Fungizides mittel enthaltend n-chlortaurin sowie dessen verwendung
US6685917B2 (en) * 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
EP1343372A2 (de) 2000-12-21 2003-09-17 Nektar Therapeutics Pulmonale verabreichung von polyene-antipilzmitteln
US7770577B2 (en) * 2001-05-15 2010-08-10 Gregory E Conner Methods and devices for treating lung dysfunction
WO2002098463A1 (fr) * 2001-06-05 2002-12-12 The New Industry Research Organization Compositions antifongiques
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
US20040019316A1 (en) * 2002-03-13 2004-01-29 Morris John K. Nasal airway delivery, decongestion system (NADDS)
WO2003103580A2 (en) * 2002-06-10 2003-12-18 Combinatorx, Incorporated Combinations for the treatment of rheumatoid arthritis
TW200402307A (en) * 2002-06-20 2004-02-16 Novartis Consumer Health Sa Nasal composition
US20050032896A1 (en) * 2002-06-21 2005-02-10 Liisa Neumann Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism
EP1519719A1 (de) * 2002-07-02 2005-04-06 Novartis AG Methoden zur behandlung von sinusitis
US20040029893A1 (en) * 2002-07-23 2004-02-12 Lane Edward M. Method of treatment of non-invasive mucositis
DK1539157T3 (da) 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
ES2539591T3 (es) * 2002-10-29 2015-07-02 Insmed Incorporated Liberación sostenida de antiinfectantes
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
WO2005000195A2 (en) * 2002-11-13 2005-01-06 Rosenberg Yvonne J A pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger
US6890323B1 (en) * 2002-12-03 2005-05-10 University Of Florida Small volume effusion trap
CA2511555A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
JP2006520786A (ja) 2003-03-14 2006-09-14 シネクサス， インコーポレイテッド 徐放性治療剤の洞送達
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20050159369A1 (en) * 2003-08-20 2005-07-21 Qtm Llc Method of treatment of otitis externa
US20070078116A1 (en) * 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US8192733B2 (en) * 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
WO2005022998A2 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
EP1672989B1 (de) * 2003-09-09 2012-04-25 3M Innovative Properties Company Konzentrierte antimikrobielle zusammensetzungen und verfahren
CA2538991A1 (en) * 2003-09-18 2005-03-31 Children's Medical Center Corporation Treatment of severe distal colitis
AU2004296784B2 (en) 2003-12-08 2010-12-02 Cpex Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070189978A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for dermally treating musculoskeletal pain
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
US20060009424A1 (en) * 2004-07-06 2006-01-12 Anatoly Kogan Nasaleaze
US8084445B2 (en) * 2004-08-13 2011-12-27 Schering-Plough Animal Health Corporation Pharmaceutical formulation
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US9028852B2 (en) * 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
KR100675379B1 (ko) * 2005-01-25 2007-01-29 삼성전자주식회사 프린팅 시스템 및 프린팅 방법
US8109981B2 (en) * 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
MX2007010908A (es) * 2005-03-10 2007-12-05 3M Innovative Properties Co Composiciones antimicrobianas que comprenden esteres de acidos hidroxicarboxilicos.
TW200719884A (en) * 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
US20060204558A1 (en) * 2005-03-10 2006-09-14 Kantner Steven S Antimicrobial pet wipes and methods
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
BRPI0608690B8 (pt) * 2005-03-10 2021-05-25 3M Innovative Properties Co uso de uma composição antimicrobiana
KR20080005939A (ko) 2005-04-04 2008-01-15 시네수스 인코포레이티드 부비동 이상의 치료 장치 및 방법
WO2006119292A2 (en) * 2005-04-29 2006-11-09 Henkin, Robert Methods for detection of biological substances
US8506934B2 (en) * 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8246946B2 (en) * 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
ITRM20050561A1 (it) * 2005-11-10 2007-05-11 D M G Italia S R L Soluzione otologica e metodo per la sua preparazione.
EP1965787B1 (de) * 2005-11-30 2013-04-10 Endo Pharmaceuticals Inc. Behandlung der Xerostomie mit einem schwefelhaltigen Antioxidant
LT1962805T (lt) 2005-12-08 2016-10-25 Insmed Incorporated Antiinfekcinės lipidų pagrindo kompozicijos, skirtos plaučių infekcijų gydymui
US20070226012A1 (en) * 2005-12-13 2007-09-27 Naryx Pharma, Inc. Methods of measuring symptoms of chronic rhinosinusitis
EP2001438A2 (de) 2006-02-09 2008-12-17 Macusight, Inc. Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung
US20070219600A1 (en) * 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
JP5600432B2 (ja) * 2006-04-06 2014-10-01 インスメッド， インコーポレイテッド コアセルベート化誘導リポソーム被包法及びその調合物
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US8535707B2 (en) 2006-07-10 2013-09-17 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
US20080131420A1 (en) * 2006-07-13 2008-06-05 Accentia, Inc. Methods and compositions for treating mucosal inflammation
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
US20080107723A1 (en) * 2006-09-28 2008-05-08 Perkins Walter R Methods of Treating Pulmonary Distress
EP2079306A4 (de) * 2006-10-03 2009-12-30 Accentia Biopharmaceuticals In Nicht schleimhautreizende amphotericin-b-formulierungen und verfahren zur behandlung nicht invasiver pilzinduzierter mucositis
BRPI0716325A2 (pt) 2006-10-27 2014-03-04 3M Innovative Properties Co Composição antimicrobianas
US20110146671A1 (en) * 2006-12-01 2011-06-23 James Zhou Liu Pharmaceutical compositions and methods of delivering the same
US8293489B2 (en) * 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
JP2010526088A (ja) * 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US8585731B2 (en) 2007-12-18 2013-11-19 Intersect Ent, Inc. Self-expanding devices and methods therefor
CN101214221A (zh) * 2007-12-27 2008-07-09 黄明 治疗鼻炎鼻窦炎药物制剂
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
EA201071137A1 (ru) 2008-03-28 2011-04-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы лечения
WO2009146104A1 (en) * 2008-04-02 2009-12-03 Accentia Biopharmaceuticals, Inc. Formulations, devices and methods for treating and preventing mucositis
MX2010011545A (es) 2008-04-21 2011-04-11 Otonomy Inc Formulaciones para tratar enfermedades y afecciones del oido.
WO2009139924A2 (en) 2008-05-14 2009-11-19 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
MX2011000862A (es) * 2008-07-21 2011-03-15 Otonomy Inc Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos.
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2320832A4 (de) 2008-08-01 2015-07-29 Intersect Ent Inc Verfahren und vorrichtungen zum crimpen selbstexpandierender vorrichtungen
CA3001814C (en) 2009-05-15 2020-12-22 Intersect Ent, Inc. Expandable devices and methods therefor
WO2011100170A1 (en) * 2010-02-10 2011-08-18 Albert Cha Nasal irrigation systems
US20120003300A1 (en) * 2010-06-30 2012-01-05 Pangaea Laboratories Ltd Composition Comprising Vascular Endothelial Growth Factor (VEGF) for the Treatment of Hair Loss
US9669044B2 (en) 2010-12-14 2017-06-06 Utah State University Aminoglycoside and azole compositions and methods
CN110075310A (zh) 2011-12-20 2019-08-02 维奥姆治疗有限公司 用于治疗真菌感染的局部油组合物
CN108743537B (zh) 2012-05-21 2021-06-11 英斯麦德公司 治疗肺部感染的系统
RU2675859C2 (ru) 2012-11-29 2018-12-25 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
EP2968877B1 (de) 2013-03-14 2020-01-01 Intersect ENT, Inc. Systeme und vorrichtungen zur behandlung eines sinusleidens
JP2016520086A (ja) * 2013-05-17 2016-07-11 ユタ ステート ユニバーシティ アミノグリコシドおよびアゾール組成物および方法
CN104208701A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有抗真菌药物的复方吸入制剂
FR3009622B1 (fr) * 2013-08-09 2015-08-07 Novacyt Procede et dispositif de lavage d'un dispositif de pipetage-distribution
KR20160047490A (ko) 2013-08-27 2016-05-02 오토노미, 인코포레이티드 소아 귀 질환의 치료
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
EP3142643B1 (de) 2014-05-15 2019-07-10 Insmed Incorporated Verfahren zur behandlung von pulmonaler mykobakterieller nichttuberkuloseinfektionen
JP6681894B2 (ja) * 2014-11-21 2020-04-15 エフツージー リミテッド 抗真菌剤
US20180071281A1 (en) * 2016-08-19 2018-03-15 Gerbe Labs Inc. Treating chronic rhinosinusitis
EP3512513A4 (de) 2016-09-16 2020-04-15 Otonomy, Inc. Gelformulierungen für das ohr zur behandlung von otitis externa
BR112019025736A2 (pt) 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
CN112040950A (zh) * 2018-03-19 2020-12-04 上海偕怡医药科技有限公司 治疗特发性肺纤维化的方法和组合物
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN111249219B (zh) * 2018-11-30 2023-08-11 中南大学湘雅三医院 治疗耳道真菌的滴耳液及其制备方法
WO2020176754A1 (en) * 2019-02-27 2020-09-03 Oticara, Inc. Method for treating nasal, sinonasal, and nasopharyngeal tissue infection and/or inflammation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US4209447A (en) 1975-01-27 1980-06-24 Janssen Pharmaceutica N.V. Imidazole derivatives and intermediates in their preparation
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
US4402957A (en) 1979-04-04 1983-09-06 Janssen Pharmaceutica N.V. Heterocyclic derivatives of [4-(piperazin-1-ylphenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4334538A (en) 1979-12-12 1982-06-15 Juhn Steven K Aspirator for collecting liquid samples
US4432991A (en) 1981-07-13 1984-02-21 American Cyanamid Company Therapeutically active 3-amino-1-phenyl(and substituted phenyl)-2-pyrazolines
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5075309A (en) 1989-06-09 1991-12-24 Janssen Pharmaceutica N.V. Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5310545A (en) * 1991-04-11 1994-05-10 Drore Eisen Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
US5248504A (en) 1992-03-02 1993-09-28 Friedman William H Method of treatment for nasal and sinus dysfunction
DK0659073T3 (da) 1992-09-10 2002-03-11 Childrens Medical Center Bionedbrydelige polymermatrixer med vedvarerende afgivelse af lokalanæstetika
CA2106034A1 (en) 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
ES2098921T3 (es) 1993-01-21 1997-05-01 Janssen Pharmaceutica Nv Composiciones de cetoconazol de uso topico.
RU2128053C1 (ru) 1993-03-19 1999-03-27 Налепо Лидия Филимоновна Средство для лечения бронхиальной астмы (варианты)
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
US5582167A (en) 1994-03-02 1996-12-10 Thomas Jefferson University Methods and apparatus for reducing tracheal infection using subglottic irrigation, drainage and servoregulation of endotracheal tube cuff pressure
US5952314A (en) * 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
US5880101A (en) * 1994-06-28 1999-03-09 Dr. Zerle Gmbh Clinical uses of polyene macrolides
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
US5679648A (en) * 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5614206A (en) 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
JP3434396B2 (ja) * 1995-06-30 2003-08-04 株式会社日立ユニシアオートモティブ 鼻腔用投薬器
GB9514878D0 (en) 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
DE19541815B4 (de) * 1995-11-09 2008-04-10 Bannert, Christian, Dr. Verwendung einer Lösung von Polyethylenglykol in Wasser als wässrige Spüllösung zur Prävention oder Behandlung von zähem Schleim, der in Verbindung mit Strahlen- oder/und Chemotherapie-induzierten Erkrankungen der Schleimhäute auftritt
US5756127A (en) 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
RU2139707C1 (ru) 1996-12-24 1999-10-20 ОАО Нижегородский химико-фармацевтический завод Суппозитории, обладающие противогрибковым действием (варианты)
PL340606A1 (en) * 1997-10-22 2001-02-12 Jens Ponikau Methods of and materials for treating and preventing mucositis
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
JP2002501780A (ja) 1998-01-30 2002-01-22 ウィルク パテント デベロップメント コーポレイション 心筋横断式冠動脈バイパスおよび血管再生術

Also Published As

Publication number Publication date
US6291500B2 (en) 2001-09-18
HK1029935A1 (en) 2001-04-20
PL340606A1 (en) 2001-02-12
KR20060002015A (ko) 2006-01-06
JP2006096770A (ja) 2006-04-13
US20090253645A1 (en) 2009-10-08
KR20060066753A (ko) 2006-06-16
ATE371457T1 (de) 2007-09-15
HUP0004170A2 (hu) 2001-05-28
BR9814615A (pt) 2001-10-16
NO325714B1 (no) 2008-07-07
CN1282251A (zh) 2001-01-31
AP2000001805A0 (en) 2000-06-30
US20020052390A1 (en) 2002-05-02
EP1024814B1 (de) 2007-08-29
CA2308201C (en) 2010-09-28
JP2007008951A (ja) 2007-01-18
BG104371A (en) 2000-12-29
EA200000439A1 (ru) 2000-12-25
EP1857113A2 (de) 2007-11-21
EP1857113A3 (de) 2007-12-19
DE69838338T2 (de) 2008-05-21
HUP0004170A3 (en) 2001-12-28
WO1999020261A2 (en) 1999-04-29
EE200000253A (et) 2001-06-15
NO20002069L (no) 2000-06-21
EP1024814A2 (de) 2000-08-09
US20010002400A1 (en) 2001-05-31
US20010031779A1 (en) 2001-10-18
JP2001520188A (ja) 2001-10-30
CA2308201A1 (en) 1999-04-29
KR100883149B1 (ko) 2009-02-10
US6555566B2 (en) 2003-04-29
OA11351A (en) 2003-12-18
WO1999020261A3 (en) 2000-02-17
US20050124561A1 (en) 2005-06-09
IL135774A0 (en) 2001-05-20
PT1024814E (pt) 2007-11-29
AU1195999A (en) 1999-05-10
US20030091510A1 (en) 2003-05-15
ID26104A (id) 2000-11-23
DK1024814T3 (da) 2008-01-02
IL135774A (en) 2006-08-20
US6207703B1 (en) 2001-03-27
IS5463A (is) 2000-04-19
ES2292210T3 (es) 2008-03-01
US20030153516A1 (en) 2003-08-14
CN1143679C (zh) 2004-03-31
NO20002069D0 (no) 2000-04-19
US20010006944A1 (en) 2001-07-05
KR20070069220A (ko) 2007-07-02
TR200001117T2 (tr) 2000-09-21
KR20010031363A (ko) 2001-04-16
SK5732000A3 (en) 2000-10-09

Similar Documents

Publication Publication Date Title
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69836640D1 (de) Vorrichtung zur behandlung von gewebe mit mehrfach-elektroden
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE69926385D1 (de) Behandlung von geweben
DE69634519D1 (de) Katheter zur ablation von atrio-ventikulären gewebe
DE60141230D1 (de) Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATA46794A (de) Einrichtung zur behandlung von hautzonen
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESE, US

8364 No opposition during term of opposition